The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index; 5 of the 30 sources its claims cite were checked for support.
Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
Open accessAbstract
BACKGROUND: Intensified multifactorial intervention - with tight glucose regulation and the use of renin-angiotensin system blockers, aspirin, and lipid-lowering agents - has been shown to reduce the risk of nonfatal cardiovascular disease among patients with type 2 diabetes mellitus and microalbuminuria. We evaluated whether this approach would have an effect on the rates of death from any cause and from cardiovascular causes. METHODS: In the Steno-2 Study, we randomly assigned 160 patients with type 2 diabetes and persistent microalbuminuria to receive either intensive therapy or conventional therapy; the mean treatment period was 7.8 years. Patients were subsequently followed observationally for a mean of 5.5 years, until December 31, 2006. The primary end point at 13.3 years of follow-up was the time to death from any cause. RESULTS: Twenty-four patients in the intensive-therapy group died, as compared with 40 in the conventional-therapy group (hazard ratio, 0.54; 95% confidence interval [CI], 0.32 to 0.89; P=0.02). Intensive therapy was associated with a lower risk of death from cardiovascular causes (hazard ratio, 0.43; 95% CI, 0.19 to 0.94; P=0.04) and of cardiovascular events (hazard ratio, 0.41; 95% CI, 0.25 to 0.67; P<0.001). One patient in the intensive-therapy group had progression to end-stage renal disease, as compared with six patients in the conventional-therapy group (P=0.04). Fewer patients in the intensive-therapy group required retinal photocoagulation (relative risk, 0.45; 95% CI, 0.23 to 0.86; P=0.02). Few major side effects were reported. CONCLUSIONS: In at-risk patients with type 2 diabetes, intensive intervention with multiple drug combinations and behavior modification had sustained beneficial effects with respect to vascular complications and on rates of death from any cause and from cardiovascular causes. (ClinicalTrials.gov number, NCT00320008.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 of 30 cited sources checked · 1 supported · 0 flagged · accuracy not yet measured
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“However, trials of interventions for single risk factors have shown efficacy in reducing the development and progression of complications.[4][5][6][7][8][9]”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Abstract
What the sources say
- Not checked — no full text of the sourcecites [4] source
- Supportedcites [5] source
The Discussion reports that tighter blood-pressure control in patients with hypertension and type 2 diabetes reduced the risk of diabetes-related complications. The Analyses of surrogate end points section also reports less deterioration in retinopathy, supporting the claim about progression. This paper establishes the point for blood pressure as a single risk factor, not for every intervention cited in the sentence. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [6] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Furthermore, the risk of vascular complications was reduced by about half in the Steno-2 Study, our previous prospective, randomized, open-label, blinded trial, during an average of 7.8 years of intensified multitarget intervention aimed at concomitant risk factors.10”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Abstract
What the sources say
- Could not verifycites [10] sourceExperimental — accuracy not yet measured
The Glycemic goals section discusses intensive treatment and vascular complications in other studies, but it does not report the Steno-2 result. Searches of our copy for Steno, 7.8 years, and multifactorial intervention found no passage giving the claimed duration or approximately halved risk. (LLM, conf=0.76)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Intensified multifactorial intervention -with tight glucose regulation and the use of renin-angiotensin system blockers, aspirin, and lipid-lowering agents -has been shown to reduce the risk of nonfatal cardiovascular disease among patients with type 2 diabetes mellitus and microalbuminuria.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Abstract
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The CVD section (page unavailable) says reducing cardiovascular risk factors can prevent or slow CVD and reports cardiovascular benefits from lipid-lowering and blood-pressure treatment. The antiplatelet section also reports that aspirin helps prevent cardiovascular events. The copy does not establish that the specified combined intervention reduced nonfatal CVD specifically in patients with type 2 diabetes and microalbuminuria. (LLM, conf=0.84)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“However, few serious adverse effects were reported during regular interviews with patients.10,12”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Dis cus sion
What the sources say
- Could not verifycites [10] sourceExperimental — accuracy not yet measured
The ‘C. Older individuals’ section discusses the risk of serious adverse effects from hypoglycemia, but does not report how many adverse effects occurred. Searches for regular patient interviews and reports of few serious adverse effects found no passage addressing either point. (LLM, conf=0.76)
- Not matchedcites [12]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Could not verify
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Progression of diabetic retinopathy occurred in 41 patients in the intensive-therapy group and in 54 patients in the conventional-therapy group (relative risk, 0.57; 95% CI, 0.37 to 0.88; P = 0.01).”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > 586
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“During the entire observation period, diabetic nephropathy developed in 20 patients in the intensive-therapy group, as compared with 37 patients in the conventional-therapy group (relative risk, 0.44; 95% CI, 0.25 to 0.77; P = 0.004) (Fig. 4).”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > 586
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The average number of recurrent events among patients with cardiovascular events was 2.0 in the intensive-therapy group and 3.3 in the conventional-therapy group.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > 586
Strength:plain· not yet calibratedn = 48Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the end of the follow-up period, the differences in risk factors between the groups had narrowed, primarily because of intensified treatment among patients in the original conventional-therapy group (Fig. 1A).”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > R e sult s
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Intensive therapy was associated with a lower risk of death from cardiovascular causes (hazard ratio, 0.43; 95% CI, 0.19 to 0.94; P = 0.04)”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean number of major cardiovascular events was 0.6 in the intensive-therapy group and 2.0 in the conventional-therapy group.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > 586
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 26
- Probably not a substantial claim. 26
- The quote only partly states this claim. 1
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“hypertensive agents, and lipid-lowering drugs each reduced the relative risk of cardiovascular events by about 25%, and the effects appeared to be additive.21,22”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Dis cus sion
What the sources say
- Not checked — no full text of the sourcecites [21] source
- Partly supportedcites [22] sourceExperimental — accuracy not yet measured
The Results section says that medications lowering cholesterol and blood pressure are proven interventions that reduce cardiovascular risk. It does not report a roughly 25% reduction for each drug class, address aspirin’s effect, or say the effects are additive. No page number is available in our copy. (LLM, conf=0.80)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Twenty-four patients in the intensive-therapy group died, as compared with 40 in the conventional-therapy group (hazard ratio, 0.54; 95% confidence interval [CI], 0.32 to 0.89; P = 0.02).”
- Also stated in: § 586 · plain
“During the entire 13.3 years of follow-up, 24 patients (30%) in the intensive-therapy group died, as compared with 40 patients (50%) in the conventional-therapy group, which corresponded to an absolute risk reduction of 20% (P = 0.02 by the log-rank test) (Fig. 3A).”
- Also stated in: § 586 · plain
“The hazard ratio for death in the intensive-therapy group, as compared with the conventional-therapy group, was 0.54 (95% confidence interval [CI], 0.32 to 0.89; P = 0.02).”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § 586 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 209 cardiovascular events occurred during the 13.3 years of observation (Table 2 and Fig. 3B).”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > 586
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Deaths from cancer were as expected on the basis of data from the Danish Cancer Registry and did not differ significantly between the two study groups (two deaths in the intensivetherapy group and five in the conventional-therapy group).”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > 586
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No significant differences were observed between the two groups with respect to habits related to exercise and smoking, and only minor (although significant) changes were seen in the intake of carbohydrates and fat.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > 586
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were also no significant differences in body weight or waist circumference (Table 1).”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > 586
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, risk factors in the intensive-therapy group remained the same as they had been during the original trial, except for systolic blood pressure, which increased”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > R e sult s
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one. The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The hazard ratio for death from cardiovascular disease tended to decrease in the intensive-therapy group after the end of the original trial, but the difference between the groups did not reach significance (P = 0.06).”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > 586
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Reductions in the progression of microvascular complications occurred after a mean of 3.8 years of intensified intervention, 12 changes that were maintained at 13.3 years.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Dis cus sion
What the sources say
- Not matchedcites [12]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“During the 13.3 years of observation, at least one minor episode of symptomatic hypoglycemia was reported in 80% of patients in the intensivetherapy group and in 70% of patients in the conventional-therapy group (P = 0.15).”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > 586
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Two patients in the intensive-therapy group and one in the conventional-therapy group reported having muscle pain after statin treatment; however, no elevation of the serum creatine kinase level was seen.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > 586
Strength:plain· not yet calibratedn = 2Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Only the control of systolic blood pressure deteriorated in the intensive-therapy group, whereas glucose levels, lipid levels, diastolic blood pressure, and the rate of urinary albumin excretion improved in the conventional-therapy group, leaving the two study groups with similar levels of risk factors after 13.3 years.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Dis cus sion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The average number of physicianprescribed drugs for type 2 diabetes or its complications in the intensive-therapy group at the end of the follow-up period was 5.5, as compared with 5.7 in the conventional-therapy group (P = 0.64).”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > 586
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Therefore, the reductions in riska 59% reduction in the relative risk and a 29% reduction in the absolute risk -in the composite of cardiovascular events fit with projections from trials involving single risk factors.21”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Dis cus sion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A bleeding gastric ulcer developed in one patient in the intensive-therapy group.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > 586
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Five patients in the intensive-therapy group and four patients in the conventional-therapy group reported having a cough during treatment with angiotensin-converting-enzyme inhibitors.The cough disappeared in all patients after a change to an angiotensin II antagonist.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > 586
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The drugs used in our study differed between the study groups.For instance, a larger proportion of patients in the intensive-therapy group took metformin or sulfonylurea, despite the similar levels of glycemia in the two groups.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Dis cus sion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“The rate of death among patients with type 2 diabetes is approximately twice as high as that among persons without the disorder.2,3”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Abstract
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“It was estimated that this plan for analyzing death from any cause would provide a statistical power of 0.75 and a type I error rate of 0.05 in detecting a reduction in the relative risk of death of 40% in the intensive-therapy group.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Statistical Analysis
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The need for laser treatment of either proliferative retinopathy or macular edema was evaluated by ophthalmologists at the eye clinic of the Steno Diabetes Center, who were unaware of study-group assignments.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Procedures, Measurements, and End Points
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Data regarding tertiary end points were censored according to prespecified intervals and analyzed with the use of a proportional-hazards model, with adjustment for age, duration of diabetes, sex, and microvascular status at baseline; these results are expressed as relative risks.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Statistical Analysis
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“An independent committee whose members were unaware of study-group assignments from the intervention portion of the Steno-2 Study adjudicated the specified end points.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Procedures, Measurements, and End Points
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In at-risk patients with type 2 diabetes, intensive intervention with multiple drug combinations and behavior modification had sustained beneficial effects with respect to vascular complications and on rates of death from any cause and from cardiovascular causes.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The mortality benefit observed during the observational follow-up is attributable to the original randomized intensive therapy, despite the conventional-therapy group receiving intensified treatment after the trial and the narrowing of risk-factor differences.
- Rests on an assumption: The results from this trial population of white Danish patients with type 2 diabetes and persistent microalbuminuria generalize to the broader population of at-risk patients with type 2 diabetes.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The measurements were obtained by a single laboratory technician who was not aware of the original studygroup assignments.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Procedures, Measurements, and End Points
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Three patients withdrew during follow-up because they moved to other regions: one patient in the intensive-therapy group withdrew after 3.2 years, and two patients in the conventional-therapy group withdrew after 0.4 and 4.7 years.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Procedures, Measurements, and End Points
Strength:plain· not yet calibratedn = 3Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the 160 patients who were enrolled in the Steno-2 Study, 27 died and 3 (including 1 patient in the intensive-therapy group) withdrew before the end-of-trial examinations in 2001.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Study Population
Strength:plain· not yet calibratedn = 160Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The protocol for the follow-up trial specified that no analyses of death from any cause would be performed until at least 60 patients had died, as verified by online death registration, and until at least half the patients in either the intensive-therapy group or the conventional-therapy group had died.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Statistical Analysis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Diabetic retinopathy was graded according to the six-level grading scale of the European Community-funded Concerted Action Programme into the Epidemiology and Prevention of Diabetes (EURODIAB) by two independent eye specialists who were unaware of the patients' study-group assignments”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Procedures, Measurements, and End Points
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All end points were analyzed according to the intention-to-treat principle.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Statistical Analysis
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“No other patients were lost to follow-up.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Procedures, Measurements, and End Points
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“At follow-up examination, 84% of patients in the intensive-therapy group and 87% of those in the conventional-therapy group were still being treated at diabetes clinics.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Study Population
Strength:plain· not yet calibratedn = 130Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“T ype 2 diabetes mellitus is associated with a high rate of complications related to cardiovascular disease and diabetic nephropathy, retinopathy, and neuropathy.[1][2][3]”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Abstract
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In the DCCT follow-up trial, glucose regulation deteriorated in the original intensive-therapy group and improved in the control group, resulting in a convergence of the glycemic levels in the two groups.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Dis cus sion
What the sources say
- Not checked — no full text of the sourcecites [25] source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The study encompassed treatment goals similar to those recommended in the current guidelines of the American Diabetes Association.11”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Abstract
What the sources say
- Not checked — no full text of the sourcecites [11] source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Recent surveys have shown very slow progress in achieving treatment goals and in the use of recommended drugs for the prevention of diabetic vascular complications.31,32”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Dis cus sion
What the sources say
- Not matchedcites [31]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [32]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore, since intensive, multifactorial care of patients with type 2 diabetes leads to reduced rates of death and cardiovascular disorders, the early and meticulous implementation of current treatment guidelines remains a major challenge.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Dis cus sion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“The effect of blood-pressure reduction on cardiovascular end points usually occurs within months, 26,27 whereas the effect of lipid lowering is evident after 1 to 2 years.8,28,29”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Dis cus sion
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Indeed, during continuous follow-up, this reduction translated into a significant absolute risk reduction of 6.3% in the need for dialysis, a condition that in many parts of the world is tantamount to death.30”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Dis cus sion
What the sources say
- Not matchedcites [30]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
In the paper
“It is man-datory by law for a physician to complete a death certificate for any death occurring in Denmark; the data are coded and retained in the computerized Danish Death Registry.16”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Procedures, Measurements, and End Points
What the sources say
- Not matchedcites [16]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We did not monitor adverse effects continuously.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Dis cus sion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“After an average follow-up of 17 years, the original intensive-therapy treatment was associated with an absolute risk reduction of 2.8% for a composite cardiovascular end point.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Dis cus sion
What the sources say
- Not checked — no full text of the sourcecites [25] source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Our study was not designed to identify which elements of intensive diabetes therapy contributed most to the reduction in cardiovascular risk.”
§ Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes > Dis cus sion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
The mortality benefit observed during the observational follow-up is attributable to the original randomized intensive therapy, despite the conventional-therapy group receiving intensified treatment after the trial and the narrowing of risk-factor differences.
“At the end of the follow-up period, the differences in risk factors between the groups had narrowed, primarily because of intensified treatment among patients in the original conventional-therapy group (Fig. 1A).”
The paper relies on this without support.
The results from this trial population of white Danish patients with type 2 diabetes and persistent microalbuminuria generalize to the broader population of at-risk patients with type 2 diabetes.
“In at-risk patients with type 2 diabetes, intensive intervention with multiple drug combinations and behavior modification had sustained beneficial effects with respect to vascular complications and on rates of death from any cause and from cardiovascular causes.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, large benefits are seen when multiple cardiovascular risk factors (glycemic, blood pressure, and lipid management) are addressed simultaneously, with evidence for long-lasting benefits (3)(4)(5).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“large benefits are seen when multiple cardiovascular risk factors (glycemic, blood pressure, and lipid management) are addressed simultaneously, with evidence for long-lasting benefits (3–5).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Numerous studies have shown the efficacy of managing individual cardiovascular risk factors in preventing or slowing ASCVD in people with diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Despite multifactorial treatment in the STENO-2 trial, renal disease still developed in 25% of patients over 13 years [15].”
In the citing paper
“Long-term follow-up (21 years from baseline) showed significantly reduced end-stage renal disease combined with death (HR 0.53; 95% CI, 0.35-0.80),and risk of HF hospitalization reduced by 70%.362”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [362]
In the citing paper
“After a further 5 years of observational follow-up this was associated with a significant reduction in cardiovascular mortality.456”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [456]
In the citing paper
“ASCVD morbidity and mortality have decreased (3,4).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [4]
In the citing paper
“Prolonged follow up showed that in some instances the benefit is retained for 10 years or more153–155”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [155]
In the citing paper
“Angiotensin-converting enzyme inhibitors812), angiotensin Ⅱ receptor blockers813), and calcium channel antagonists814) have been reported to be effective for preventing cardiovascular events in patients with DM.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [814]
In the citing paper
“Large benefits are seen when multiple risk factors are addressed globally (154).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [154]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Insulin-plus-oral therapy exceeds insulin use
MinorAt the end of follow-up in the intensive-therapy group, 83% are reported as using insulin plus an oral hypoglycemic agent, but only 73% are reported as using insulin. Combination users must be a subset of insulin users.
“| Insulin plus an oral hypoglycemic | 0 | 1 | 32 | 21 | 83 | 42 † |”
“| Insulin (%) | 6 | 14 | 57 | 54 | 73 | 82 |”
Citations
Cites
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Self-citationColhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed Diabetes
Saydah, S. H. (2004) · JAMA · doi:10.1001/jama.291.3.335 · Cited by 1,357
Flagged first, then by citations
Research works printed but not linked: 3
- Beck-Nielsen H, 2000, Ugeskr Laeger, 162, S1
- Juel K, 1999, Dan Med Bull, 46, 354
- Gaede PH, 2006, Dan Med Bull, 53, 258
Cited by
Sorted by citations
Items 1,601–1,700 of 3,457
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
Schwartz, S. S. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s11389 · Cited by 16
The Current Status of Type 2 Diabetes Management at a University Hospital
Lee, Y. S. (2009) · Korean Diabetes Journal · doi:10.4093/kdj.2009.33.3.241 · Cited by 13
Noninvasive Assessment of Lower-extremity Hemodynamics in Individuals with Diabetes Mellitus
Andersen, C. A. (2010) · Journal of the American Podiatric Medical Association · doi:10.7547/1000406 · Cited by 13
Amory, C. F., & Weinberger, J. M. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch46 · Cited by 14
Risk factors for cardiovascular events and incident hospital-treated diabetes in the population
Khalili, P. (2012) · Örebro University Library (Örebro University) · Cited by 13
Yusufu, M., Zhang, X., Sun, X., Raat, H., & Wang, N. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107834 · Cited by 12
STOUGAARD, E. B., Andersen, M. R., Bagger, J. I., Søndergaard, E., Østergaard, J. A., Curovic, V. R., Persson, F., Almdal, T., Mathiesen, A. S., Andries, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16606 · Cited by 13
Self-citationAlbuminuric diabetic kidney disease predicts foot ulcers in type 2 diabetes
Borderie, G., Foussard, N., Larroumet, A., Blanco, L., Domenge, F., Mohammedi, K., Ducasse, É., Caradu, C., & Rigalleau, V. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108403 · Cited by 11
Ali, M. F., Ja’afar, N. I. S., Krishnan, T. G., Zulkifle, M. A. M., Khaidzir, N. K., Jamil, T. R., Man, Z. C., & Aziz, A. F. A. (2023) · BMC Geriatrics · doi:10.1186/s12877-023-04230-4 · Cited by 14
Silva-Tinoco, R., Cuatecontzi-Xochitiotzi, T., Castillo‐Martínez, L., de la Torre-Saldaña, V., GUZMAN-OLVERA, E. B., & Bernal-Ceballos, F. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.07.004 · Cited by 12
Aktuelle Therapie des Typ-2-Diabetes
Schernthaner, G., & Schernthaner, G.-H. (2012) · Der Internist · doi:10.1007/s00108-012-3203-6 · Cited by 12
Glucose control and cardiovascular outcomes: reorienting approach
Khardori, R. K., & Nguyen, D. D. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00110 · Cited by 12
Chhabra, L., Liti, B., Kuraganti, G., Kaul, S., & Trivedi, N. (2013) · International Journal of Endocrinology · doi:10.1155/2013/856793 · Cited by 14
Mainar, A. S., Suárez, C. R., Ramos, B. F., Artieda, R. N., & Ibáñez, J. (2013) · Revista Clínica Española · doi:10.1016/j.rce.2013.06.003 · Cited by 12
Reinhard, H., Hansen, P. R., Wiinberg, N., et al. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-19 · Cited by 12
Self-citationIrewall, A.-L., Bergström, L., Ögren, J., Laurell, K., Söderström, L., & Mooe, T. (2014) · Cerebrovascular Diseases Extra · doi:10.1159/000358121 · Cited by 12
Bariatric and metabolic surgery and microvascular complications of type 2diabetes mellitus
COHEN, R. V., Pechy, F. N. Q., Petry, T. B. Z., Correa, J. L., Caravatto, P. P. D. P., & Tzanno‐Martins, C. (2015) · Brazilian Journal of Nephrology · doi:10.5935/0101-2800.20150061 · Cited by 12
Evaluation of the Glomerular Filtration Barrier by Electron Microscopy
de Souza, D. B., Gregório, B. M., Benchimol, M., et al. (2016) · InTech eBooks · doi:10.5772/61811 · Cited by 12
Science, clinical outcomes and the popularization of diabetes surgery
Lebovitz, H. E. (2012) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328358301f · Cited by 12
Diabetes mortality in the USA: winning the battle but not the war?
Bennett, P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30843-2 · Cited by 12
Zhang, X., Wan, G., Yuan, M., Yang, G.-R., Fu, H.-J., Zhu, L., Xie, R.-R., Lv, Y., Zhang, J., Li, Y.-L., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00782-5 · Cited by 12
Guinan, K., Beauchemin, C., Tremblay, J., Chalmers, J. P., Woodward, M., Tahir, M. R., Hamet, P., & Lachaîne, J. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.06.010 · Cited by 14
Ito, H., Antoku, S., Izutsu, T., Kusano, E., Matsumoto, S., Yamasaki, T., Mori, T., & Togane, M. (2020) · Clinical and Experimental Nephrology · doi:10.1007/s10157-020-01935-3 · Cited by 12
Tackling cardiometabolic risk in the Asia Pacific region
Li, J., Yeo, K. K., Tan, K., Ako, J., Krittayaphong, R., Tan, R., Aylward, P. E., Lam, C. S. P., Baek, S. H., Dalal, J. J., et al. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100096 · Cited by 13
The impact of lockdown caused by the COVID-19 pandemic on glycemic control in patients with diabetes
Sutkowska, E., Marciniak, D. M., Sutkowska, K., Biernat, K., Mazurek, J., & Kuciel, N. (2022) · Endocrine · doi:10.1007/s12020-022-02985-1 · Cited by 12
Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
Nicola, L. D., Cozzolino, M. G., Genovesi, S., Gesualdo, L., Grandaliano, G., & Pontremoli, R. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01336-7 · Cited by 14
Cha, S., Yun, J., Kim, G.-H., & Ahn, Y. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01651-0 · Cited by 14
Hata, S., Ushigome, E., Hosomi, Y., Yoshimura, T., Takegami, M., Kitagawa, N., Tanaka, T., Hasegawa, G., Ohnishi, M., Tsunoda, S., et al. (2023) · Hypertension Research · doi:10.1038/s41440-022-01136-3 · Cited by 13
Evans, M., Berry, S., Malkin, S. J. P., Hunt, B., & Sharma, A. K. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01408-2 · Cited by 12
Lucas, A., Guanyabens, E., Zavala-Arauco, R., Chamorro, J., Granada, M. L., Mauricio, D., & Puig‐Domingo, M. (2015) · International Journal of Endocrinology · doi:10.1155/2015/381415 · Cited by 12
Das, A., Seshiah, V., Bk, S., et al. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.104119 · Cited by 12
Aihara, K., Miyauchi, K., Kasai, T., et al. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.1925 · Cited by 12
Community pharmacy-based A1c screening: a Canadian model for diabetes care
Papastergiou, J., Folkins, C., & Li, W. (2015) · International Journal of Pharmacy Practice · doi:10.1111/ijpp.12228 · Cited by 12
The stroke east S axony pilot project for organized post‐stroke care: a case–control study
Bodechtel, U., Barlinn, K., Helbig, U., Arnold, K., Siepmann, T., Pallesen, L., Puetz, V., Reichmann, H., Schmitt, J. M., & Kepplinger, J. (2016) · Brain and Behavior · doi:10.1002/brb3.455 · Cited by 12
Kitada, M., Tsuda, S.-I., Konishi, K., Takeda‐Watanabe, A., Fujii, M., Kanasaki, K., Nishizawa, M., Nakagawa, A., & Koya, D. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000391 · Cited by 12
Kitagawa, N., Ushigome, E., Matsumoto, S., Oyabu, C., Ushigome, H., Yokota, I., Asano, M., Tanaka, M., Yamazaki, M., & Fukui, M. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13209 · Cited by 11
Johansen, P., Hunt, B., Iyer, N. N., Dang‐Tan, T., & Pollock, R. F. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00915-8 · Cited by 12
Identifying asymptomatic patients at high-risk for stroke
Gaba, K., & Bulbulia, R. A. (2019) · The Journal of Cardiovascular Surgery · doi:10.23736/s0021-9509.19.10912-3 · Cited by 12
Kim, Y. T., Chung, H. J., Park, B. R., Kim, Y. Y., Lee, J. H., Kang, D. R., Kim, J., Lee, M. Y., & Lee, J. Y. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15320 · Cited by 13
Towards precision medicine in diabetes? A critical review of glucotypes
Hulmán, Á., Foreman, Y. D., Brouwers, M. C. G. J., Kroon, A. A., Reesink, K. D., Dagnelie, P. C., Kallen, C., van Greevenbroek, M. M. J., Færch, K., Vistisen, D., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3000890 · Cited by 14
Eye Outcomes in Veteran Affairs Diabetes Trial (VADT) After 17 Years
Azad, N., Agrawal, L., Bahn, G., Emanuele, N., Reaven, P. D., Hayward, R. A., Reda, D. J., & the VADT Study Group (2021) · Diabetes Care · doi:10.2337/dc20-2882 · Cited by 13
Senior, P. A. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.09.001 · Cited by 12
Höskuldsdóttir, G., Franzén, S., Eeg‐Olofsson, K., & Eliasson, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-16135-0 · Cited by 14
Therapeutic problems in elderly patients with hemophilia
Zawilska, K., & Podolak‐Dawidziak, M. (2012) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.1466 · Cited by 12
McAdam‐Marx, C., Bouchard, J. R., Aagren, M., et al. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.01.018 · Cited by 12
Diabetic Nephropathy in the Elderly
Joseph, A. J., & Friedman, E. A. (2009) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.06.005 · Cited by 12
Intensive therapy for diabetes through influence on innate immune system
Li, Z., Liu, J., Li, L., Jiao, L., & Chen, L. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.01.028 · Cited by 12
Is tight glycemic control in type 2 diabetes really worthwhile? No.
Clement, M., Bhattacharyya, O., & Conway, J. R. (2009) · PubMed · Cited by 12
Mallat, S. G. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-108 · Cited by 13
Combination therapy for patients with Type 2 diabetes: repaglinide in combination with metformin
Moses, R. G. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.17 · Cited by 12
Diabetes and cardiovascular disease: The role of glycemic control
CHENG, A. Y. Y., & Leiter, L. A. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0012-y · Cited by 12
Predicting Renal Risk in the General Population
Taal, M. W. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04200511 · Cited by 12
Yashkin, A. P., Kravchenko, J. S., Yashin, A. I., & Sloan, F. A. (2017) · American Journal of Hypertension · doi:10.1093/ajh/hpx151 · Cited by 12
Ruilope, L. M. (2008) · Journal of Hypertension · doi:10.1097/01.hjh.0000320755.15862.b2 · Cited by 12
Wagner, E. M., Højlund, M., Fiedorowicz, J. G., Nielsen, R. E., Østergaard, S. D., Høye, A., Heiberg, I. H., Poddighe, L., Delogu, M., Holt, R. I. G., et al. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00332-3 · Cited by 12
Mathew, R. O., Maron, D. J., Anthopolos, R., Fleg, J. L., O’Brien, S. M., Rockhold, F. W., Briguori, C., Roik, M. F., Mazurek, T., Demkow, M., et al. (2022) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.122.008995 · Cited by 11
Verma, S., Sabbour, H. M., Alamuddin, N., Alawadi, F., Alkandari, H., Almahmeed, W. A., Assaad-Khalil, S. H., HADDAD, J. A., Lombard, L., Malik, R. A., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15011 · Cited by 11
Education programmes for people with chronic kidney disease and diabetes
Cashmore, B. A., Cooper, T. E., Evangelidis, N., Green, S. C., Lopez‐Vargas, P. A., & Tunnicliffe, D. J. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007374.pub3 · Cited by 11
Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study
Lindhardt, M. K., Knudsen, S. T., Saxild, T., Charles, M., & Borg, R. (2025) · BMC Family Practice · doi:10.1186/s12875-025-02721-4 · Cited by 16
Skovgaard, R., Ploug, U. J., Hunt, B., et al. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.05.496 · Cited by 11
Ji, L., Weng, J., Lu, J., et al. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0115-4 · Cited by 11
Approach to Cardiovascular Disease Prevention in Patients With Chronic Kidney Disease
Karohl, C., & Raggi, P. (2012) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-012-0189-2 · Cited by 11
Management of the Patient With Diabetes and Coronary Artery Disease: A Contemporary Review
Raymond, T. E., Raymond, R. E., & Lincoff, A. M. (2013) · Future Cardiology · doi:10.2217/fca.13.22 · Cited by 11
Kanaoka, T., Tamura, K., Moriya, T., Tanaka, K., Konno, Y., Kondoh, S., Toyoda, M., Umezono, T., Fujikawa, T., Ohsawa, M., et al. (2011) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2011.583971 · Cited by 11
Wong, A. K. Y., Stewart, A. G. O., & Furler, J. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.07.005 · Cited by 11
Royo‐Bordonada, M. Á., Armario, P., Bejarano, J. M. L., Pedro‐Botet, J., Álvarez, F. V., Elosúa, R., Cuixart, C. B., Cortés, O., Serrano, B., Babkowski, M. C., et al. (2016) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2016.11.006 · Cited by 12
Royo‐Bordonada, M. Á., Armario, P., Bejarano, J. M. L., Pedro‐Botet, J., Álvarez, F. V., Elosúa, R., Cuixart, C. B., Cortés, O., Serrano, B., Camafort, M., et al. (2017) · Gaceta Sanitaria · doi:10.1016/j.gaceta.2016.12.007 · Cited by 14
Green, M., Shah, B. R., Slater, M. B., Khan, S., Jones, C. R., & Walker, J. D. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191039 · Cited by 11
Murakami, T., Kato, S., Shigeeda, T., Itoh, H., Komuro, I., Takeuchi, M., Yoshimura, N., & for the ophthalmology substudy of EMPATHY Investigators (2020) · Eye · doi:10.1038/s41433-020-01202-5 · Cited by 11
Persson, F., Charles, M., Povlsen, J. V., & Knudsen, S. T. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.07.003 · Cited by 11
Franch‐Nadal, J., Malkin, S. J. P., Hunt, B., Martín, V., Estébanez, M. G., & Vidal, J. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02156-8 · Cited by 11
HbA1c , blood pressure, and cholesterol control in adults with diabetes: A report card for Kuwait
Alkandari, A., Gujral, U. P., Bennakhi, A., Qabazard, S., Al‐Wotayan, R., Al-Duwairi, Q., Alkandari, H., Narayan, K. V., & Alarouj, M. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13832 · Cited by 12
Lower extremity arterial disease perspective: IUA consensus document on "lead management". Part 1
Antignani, P. L., Gargiulo, M., Gastaldi, G., Jawień, A., Mansilha, A., & Poredoš, P. (2023) · International Angiology · doi:10.23736/s0392-9590.23.05110-6 · Cited by 12
Lin, J., Wu, H., Huang, W., Lu, C.-L., Cheng, M.-H., Wang, H.-T., Yen, T., & Wang, W. (2014) · Renal Failure · doi:10.3109/0886022x.2014.964140 · Cited by 11
Glycaemic control, cardiovascular disease, and mortality in type 2 diabetes
Chiasson, J., & LeLorier, J. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60884-9 · Cited by 11
Association between Pulse Wave Velocity and Nerve Conduction Study in Diabetic Patients
Suh, B. C., Chung, P., Moon, H., Kim, Y. B., Yoon, W. T., Shim, D. S., & Kim, S. B. (2010) · European Neurology · doi:10.1159/000319605 · Cited by 11
What Are New Avenues for Renal Protection, in Addition to RAAS Inhibition?
Hagiwara, S., Kantharidis, P., & Cooper, M. E. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0251-1 · Cited by 11
Baillot, A., Pelletier, C., Dunbar, P., Geiss, L. S., Johnson, J. A., Leiter, L. A., & Langlois, M. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.022 · Cited by 11
Li, Q., Feng, L., Tang, W., Ma, X., Ding, X., Mao, D., Li, J., Wang, Y., & Xiong, H. (2014) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph111111450 · Cited by 11
Sanyal, C., Graham, S. D., Cooke, C., SKETRIS, I. S., Frail, D. M., & Flowerdew, G. J. (2008) · BMC Health Services Research · doi:10.1186/1472-6963-8-111 · Cited by 10
Dang, S., Sanchez, A., Oropesa, L., Roos, B. A., & Florez, H. J. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0066 · Cited by 11
The impact of severe hypoglycemia on renal impairment in type 2 diabetes
Lee, Y.-L., Chen, B., Lin, K., Su, R.-W., Lee, M., Hsiao, P., & Shin, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.02.028 · Cited by 15
Cirurgia metabólica: mudanças na anatomia gastrointestinal e a remissão do diabetes mellitus tipo 2
COHEN, R. V., Torres, M. C., & Schiavon, C. A. (2010) · ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) · doi:10.1590/s0102-67202010000100010 · Cited by 10
Lee, J. D. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.874 · Cited by 11
Diabetes and the Cardiovascular System
McGuire, D. K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00064-0 · Cited by 12
Ding, L., Xu, Y., Wang, L., Xu, M., Jiang, Y., Zhang, M., Yichong, L., Lu, J., Wang, T., Dai, M., et al. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.10.023 · Cited by 10
Li, P.-I., Wang, J.-N., & Guo, H. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.027 · Cited by 11
Kjær, L. K., Oellgaard, J., Henriksen, T., Gæde, P., Pedersen, O. B., & Poulsen, H. E. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.09.030 · Cited by 11
Self-citationCorrales, P. J. P., Bellido, V., & Ampudia‐Blasco, F. J. (2018) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2018.12.002 · Cited by 11
Lee, Y.-L., Yen, S., Shin, S., Huang, Y.-C., He, J. S., & Lin, K. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16050681 · Cited by 12
Gao, Y., Peterson, E. D., & Pagidipati, N. J. (2019) · Clinical Cardiology · doi:10.1002/clc.23252 · Cited by 11
Nonomura, K., Iizuka, K., Kuwabara-Ohmura, Y., & Yabe, D. (2020) · Internal Medicine · doi:10.2169/internalmedicine.4323-19 · Cited by 11
Rigato, M., Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa178 · Cited by 14
Ying, D. G., Ko, S. ‐., Li, Y., & Chen, C. X. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.02.012 · Cited by 11
Bhalodkar, A., Sonmez, H., LESSER, M. L., Leung, T., Ziskovich, K., Inlall, D., Murray-Bachmann, R., Krymskaya, M., & Poretsky, L. (2020) · Endocrine Practice · doi:10.4158/ep-2020-0261 · Cited by 11
The diagnosis and management of diabetes in Australia: Does the “Rule of Halves” apply?
Sainsbury, E., Shi, Y., Flack, J. R., & Colagiuri, S. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108524 · Cited by 13
Assessment of Cardiovascular Risk Factors in Patients with Type 2 Diabetes in Upper Egypt Villages
Hussein, A. A., Mahmoud, S. E. D., Awad, M. S., et al. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s282888 · Cited by 11
Heerspink, H. J. L., Law, G., Psachoulia, K., Connolly, K., Whatling, C. A., Ericsson, H., Knöchel, J., Lindstedt, E., & MacPhee, I. A. M. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.08.018 · Cited by 14
Mendivil, C. O., Amaya-Montoya, M., Vargas, J. A. H., Ramírez-García, N., Romero-Díaz, C., Pérez-Londoño, A., Guatibonza-García, V., & Acuña-Merchán, L. A. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109823 · Cited by 15
Alicic, R. Z., Johnson, E. J., & Tuttle, K. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52978-5.00003-3 · Cited by 11
Metadata
- Authors
- Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O.
- Affiliations
- Steno Diabetes Center Copenhagen (DK)
- Aarhus University (DK)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-02-07
- Volume
- 358
- Issue
- 6
- Pages
- 580-591
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2170271198
- Cited by
- 3,465
- References
- 36
- Citations by year
- 2026: 66 · 2025: 80 · 2024: 106 · 2023: 132 · 2022: 126 · 2021: 168 · 2020: 181 · 2019: 160 · 2018: 182 · 2017: 178 · 2016: 208 · 2015: 204 · 2014: 252 · 2013: 236 · 2012: 250
- FWCI
- 181.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, tight glycemic control, multifactorial intervention, microalbuminuria, cardiovascular mortality, all-cause mortality, renin-angiotensin system inhibitors, aspirin, lipid-lowering drugs, end-stage renal disease, retinal photocoagulation
- MeSH terms
- Aged, Angiotensin-Converting Enzyme Inhibitors, Hypolipidemic Agents, Aspirin, Behavior Therapy, Cardiovascular Diseases, Cause of Death, Combined Modality Therapy, Diabetes Mellitus, Type 2, Diabetic Neuropathies, Drug Therapy, Combination, Follow-Up Studies, Humans, Hypoglycemic Agents, Middle Aged, Platelet Aggregation Inhibitors, Risk Factors, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
